Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2007

View Archived Issues

Six-plasmid HIV-1 DNA vaccine candidate advances to phase II

Bavarian Nordic reports on U.S. developments

SBIR grant supports OligoMerix's work in Alzheimer's disease

Recent Boehringer Ingelheim patent reports novel analgesic agents for migraine

Sphingozumab effective in animal models of laser-induced CNV

SQ-109 for TB completes phase Ia trial

CyDex licenses Captisol enabling technology to Sunesis for Aurora kinase inhibitor

Rare Disease Therapeutics to market Cystadane in U.S. and Canada

Peptech and Evogenix to merge

Viragen to end collaboration with Memorial Sloan-Kettering on VG-101

Ganaxolone studied for adult partial onset seizures in new phase IIb trial

Affitech and Roche sign antibody research and licensing agreement

Brazilian Government issues compulsory license on Stocrin

KAI-1455 begins phase I trial for prevention of ischemic injury

Recent patents describe new treatment options for diabetes

Novel therapeutic agents for cardiovascular disorders reported in recent patent literature

Ista withdraws European application for Vitragan

Enrollment open in phase I study of new obesity candidate trodusquemine

Aastrom cleared for phase III study of bone repair cell product in osteonecrosis

The mTOR inhibitor QLT-0447 potently suppresses CNV in vivo

Topically applied TG-101095 shows promise in a murine laser-induced CNV model

Gentamicin-induced stop codon readthrough shows benefit in a retinitis pigmentosa rat model

Q1 progress at BioMarin

Enjuvia receives two new FDA approvals

Taxus Express2 paclitaxel-eluting coronary stent system launched in Japan

E.U. approval for pandemic influenza vaccine Focetria

Pergoveris recommended for E.U. approval

Circadian recommended for E.U. approval in primary insomnia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...